Nurix Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Nurix Therapeutics, Inc.
26.85
−0.14%
vs ±17.9% implied · ×0.01
shaded = implied · ▲▼ = realized
Fund move
Fund move
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | BlackRockBlackRockindex-like | $212.8M | 7.46% | −1.74% | |
| 2 | Vestal Point CapitalVestal Point Capital | $195.3M | 6.85% | +23.85% | |
| 3 | Deep Track CapitalDeep Track Capital | $187.7M | 6.58% | +21.93% | |
| 4 | Rubric Capital ManagementRubric | $175.3M | 6.15% | +192.16% | |
| 5 | FMRFMR | $133.1M | 4.67% | −1.01% | |
| 6 | T. Rowe Price AssociatesT. Rowe Price | $131.9M | 4.63% | +65.23% | |
| 7 | Morgan StanleyMorgan Stanley | $115.5M | 4.05% | −3.44% | |
| 8 | State StreetState Streetindex-like | $113.5M | 3.98% | −9.02% | |
| 9 | Baker Bros. AdvisorsBaker Bros. | $113.0M | 3.96% | 0.00% | |
| 10 | Vanguard Capital ManagementVanguardindex-like | $109.1M | 3.82% | +1.55% | |
| 11 | Perceptive AdvisorsPerceptive | $104.8M | 3.68% | +16.43% | |
| 12 | Redmile GroupRedmile | $98.8M | 3.47% | −47.32% | |
| 13 | General AtlanticGeneral Atlantic | $73.6M | 2.58% | −26.08% | |
| 14 | Geode Capital ManagementGeodeindex-like | $61.6M | 2.16% | +0.68% | |
| 15 | Pictet Asset Management HoldingPictet | $57.0M | 2.00% | −13.75% | |
| 16 | ARK Investment ManagementARK | $43.5M | 1.53% | +4.19% | |
| 17 | Capital World InvestorsCapital World Investors | $43.4M | 1.52% | +100.14% | |
| 18 | Trails Edge Capital PartnersTrails Edge Capital Partners | $38.2M | 1.34% | −9.75% | |
| 19 | Citadel AdvisorsCitadel | $37.1M | 1.30% | +10.80% | |
| 20 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $36.0M | 1.26% | +34.53% | |
| 21 | Soleus Capital ManagementSoleus | $35.5M | 1.25% | +56.17% | |
| 22 | Dimensional Fund AdvisorsDimensional | $34.7M | 1.22% | +83.34% | |
| 23 | Eventide Asset ManagementEventide | $31.5M | 1.10% | 0.00% | |
| 24 | BraidwellBraidwell | $31.2M | 1.09% | −26.50% | |
| 25 | Kynam Capital ManagementKynam | $29.0M | 1.02% | 0.00% |
212 managers report $2.9B of Nurix Therapeutics on form 13F for the quarter ended Jun 30 '26. 27 of them hold 80% of it; BlackRock is largest at 7.46%.
No implied move.
No implied move.
Expected move
No implied move.
Linked news